Context

Genfit is a leading Phase III biopharmaceutical company dedicated to the development of innovative therapeutics and diagnostics for liver related diseases, especially NASH (Non-Alcoholic Steatohepatitis), affecting ~20 million people in the US.

Efficacy of elafibranor was demonstrated in Phase II, which also showed good tolerability and improved cardiometabolic profile in NASH patients.

Results of ongoing elafibranor registrational Phase III trial in NASH are expected at the end of 2019. An approval could position elafibranor as one of the first ever treatments in this indication.

Other clinical programs include Phase III-ready elafibranor in PBC (Primary Biliary Cholangitis) and Phase II Nitazoxanide in NASH-induced fibrosis.

IPO proceeds will be used to complete the ongoing Phase III of elafibranor in NASH, prepare its launch by building a commercial infrastructure, advance its clinical investigations in PBC and as a backbone for NASH combination therapy.

About Genfit

GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees. GENFIT is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: GNFT – ISIN: FR0004163111).

Discover Genfit

Hervé Ronin

Investment Banking

Cosme Rosellini

Investment Banking

Pierre Kiecolt-Wahl

Investment Banking

Dr. Mickael Dubourd

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center